Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.

BMC Cancer 2017 Jun 15;17(1):415. Epub 2017 Jun 15.

Division of Clinical Oncology; Department of Medicine; Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.

Background: Venous thromoboembolism (VTE) is a frequent and burdensome complication of metastatic colorectal cancer (CRC). However, the epidemiology of VTE in patients with localized CRC after surgery in curative intent is incompletely understood. In this single-center observational cohort study, we investigate patterns of VTE risk in localized CRC, and define its relationship with baseline risk factors, adjuvant chemotherapy and CRC recurrence.

Methods: Five-hundred-sixteen patients with stage II/III CRC were included retrospectively at the time of surgery, and followed until the occurrence of VTE, CRC recurrence, or death (median age = 65.1 years, stage II and III: n = 151 (29.5%), n = 361 (70.5%); adjCTX: n = 339 (65.7%)).

Results: During a median follow-up of 2.7 years, 15 VTEs (2.7%) and 116 recurrences (22.5%) occurred, and 46 patients (8.9%) died. Six-month, 1-year, and 5-year VTE risks were 1.6%, 2.0% and 3.2%, respectively. In competing risk time-to-VTE regression, adjCTX was not associated with an increased risk of VTE (Subdistribution hazard ratio = 0.98, 95% CI:0.33-2.88, p = 0.97). The occurrence of disease recurrence strongly increased the risk of VTE (Multi-state model: Transition hazard ratio (THR) = 13.03, 95% CI:4.39-38.74, p < 0.0001)). Conversely, the onset of VTE did not predict for recurrence (THR = 1.95, 95% CI: 0.62-6.16, p = 0.25).

Conclusion: VTE risk is very low in localized CRC and does not appear to be increased by adjuvant chemotherapy. Thus, primary thromboprophylaxis is unlikely to result in clinical benefit in this population. The strongest determinant of VTE risk appears to be disease recurrence.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3392-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471923PMC
June 2017
42 Reads

Publication Analysis

Top Keywords

adjuvant chemotherapy
8
colorectal cancer
8
patients localized
8
cohort study
8
observational cohort
8
increased risk
8
risk vte
8
localized crc
8
vte
7
risk
6
crc
6
n = 361 705%
4
116 recurrences
4
recurrences 225%
4
225% occurred
4
705% adjctx
4
295% n = 361
4
adjctx n = 339
4
n = 151 295%
4
follow-up 27 years
4

References

(Supplied by CrossRef)

AA Khorana et al.
2007

T Wun et al.
Best Pract res Clin Haematol Netherlands 2009

HK Chew et al.
J Thromb Haemost England 2008

K Kroger et al.
Ann Oncol England 2006

G Numico et al.
Cancer United States 2005

R Labianca et al.
2013

Similar Publications